Sartorius buys Cellca for process dev knowhow

By Gareth Macdonald contact

- Last updated on GMT

Sartorius buys Cellca for process dev knowhow

Related tags: Process development, Biotechnology

Sartorius Stedim Biotech SA (SSB) has acquired cell line and process development contractor Cellca GmbH.

The acquisition – terms of which were not made public – saw long time Cellca investors Kreissparkasse Biberach and KfW​ sell their stakes to SSB.

SSB said the purchase was motivated by Cellca’s process development business adding that it would further strengthen its offering following the acquisitions of BioOutsource​ and TAP Biosystems​.

Laupheim, Germany-based Cellca targets biopharmaceutical firms that lack capacity for in-house process development. The firm also provides cell line development services that are focused around the popular Chinese hamster ovary (CHO) cell line.

Cellca describes both GE Healthcare Bio-Sciences and Rentschler Biotechnology as important industry partners.

Process development

SSB – which is due to hold its half-year update conference later this month – markets itself as ‘total solutions provider’ to the biopharmaceutical manufacturing sector.

Commenting on the Cellca acquisition, Reinhard Vogt, a member of the SSB Executive Committee for Marketing and Sales, said: “Together with our single-use products, media and testing services, we are creating an attractive package, above all for young biopharmaceutical companies that need robust processes for the manufacture of their biologics.​"

The TAP takeover in 2013 added two small-volume, single-use bioreactor systems​ to SSB’s portfolio enabling it to offer biopharmaceutical industry customers the ability to conduct a large number of cell culture experiments in parallel.

BioOutsource, which was acquired by SSB in April​, is a contract research organisation (CRO) that provides process development and analytical services.

Related news

Show more

Related products

show more

Infographic - road map to commercialization

Infographic - road map to commercialization

MilliporeSigma - Gene Therapy | 19-Oct-2020 | Infographic

With the current increase in development and investment, gene therapy companies will increasingly be looking to streamline the manufacture and commercialization...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Process Development for Viral Vector Manufacturing

Process Development for Viral Vector Manufacturing

MilliporeSigma - Gene Therapy | 15-Oct-2020 | Infographic

Process development is a crucial step in viral vector manufacturing and a successful CDMO partnership can help navigate the challenges associated with...

Related suppliers

Follow us

Products

View more

Webinars